Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by BidaskClub to “Buy”

BidaskClub upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a buy rating in a research note issued to investors on Thursday, BidAskClub reports.

Several other analysts have also commented on the company. Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. Jefferies Financial Group set a $46.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a report on Friday, August 30th. Cowen set a $50.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a report on Wednesday, August 7th. Stifel Nicolaus set a $55.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a report on Wednesday, August 7th. Finally, TheStreet lowered Supernus Pharmaceuticals from a b- rating to a c+ rating in a report on Thursday, August 29th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $53.38.

Supernus Pharmaceuticals stock traded down $0.33 during midday trading on Thursday, hitting $27.56. 28,418 shares of the company were exchanged, compared to its average volume of 484,017. The firm has a market capitalization of $1.47 billion, a PE ratio of 13.46, a price-to-earnings-growth ratio of 0.98 and a beta of 1.62. Supernus Pharmaceuticals has a fifty-two week low of $25.32 and a fifty-two week high of $51.38. The business has a fifty day simple moving average of $28.86 and a two-hundred day simple moving average of $33.29. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.53 and a current ratio of 2.72.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.56 by $0.05. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $109.67 million. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. Supernus Pharmaceuticals’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $0.57 earnings per share. As a group, equities analysts expect that Supernus Pharmaceuticals will post 2.16 earnings per share for the current year.

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar acquired 7,200 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $26.39 per share, with a total value of $190,008.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.57% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 588,259 shares of the specialty pharmaceutical company’s stock valued at $19,541,000 after purchasing an additional 44,268 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Supernus Pharmaceuticals by 870.5% in the first quarter. BNP Paribas Arbitrage SA now owns 11,345 shares of the specialty pharmaceutical company’s stock worth $398,000 after acquiring an additional 10,176 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Supernus Pharmaceuticals by 6.8% in the first quarter. Alps Advisors Inc. now owns 10,532 shares of the specialty pharmaceutical company’s stock worth $369,000 after acquiring an additional 666 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Supernus Pharmaceuticals by 0.4% in the first quarter. Rhumbline Advisers now owns 144,963 shares of the specialty pharmaceutical company’s stock worth $5,080,000 after acquiring an additional 616 shares during the last quarter. Finally, Comerica Bank boosted its stake in shares of Supernus Pharmaceuticals by 2.8% in the first quarter. Comerica Bank now owns 52,153 shares of the specialty pharmaceutical company’s stock worth $2,014,000 after acquiring an additional 1,436 shares during the last quarter. 99.35% of the stock is currently owned by institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Further Reading: Are analyst ratings accurate?

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.